[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • The role of postoperative adjuvant chemotherapy is not well documented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


2. des Guetz G, Chapelier A, Mosseri V, Dorval T, Asselain B, Pouillart P: Postirradiation sarcoma: clinicopathologic features and role of chemotherapy in the treatment strategy. Sarcoma; 2009;2009:764379
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postirradiation sarcoma: clinicopathologic features and role of chemotherapy in the treatment strategy.
  • Purpose. An analysis of the clinicopathologic features and treatment of patients was performed to guide evaluation and management of postirradiation sarcoma.
  • Between 1994 and 2001, 25 patients with postirradiation sarcoma were treated in one center with different chemotherapy, mainly in neoadjuvant setting (19).
  • Tumors for which these patients received radiotherapy initially were mainly breast carcinoma (for 15 patients).
  • The postirradiation sarcomas were of different histopathologic forms, most frequently osteosarcoma, leiomyosarcoma, and angiosarcoma.
  • Results. Of the 25 patients, 19 were initially treated with chemotherapy.
  • Chemotherapy has to be included in the treatment plan of postirradiation sarcoma, in future studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] J Surg Oncol. 1985 Mar;28(3):168-71 [3838353.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:325-9 [4088306.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] J Surg Oncol. 1994 Nov;57(3):171-7 [7967606.001]
  • [Cites] Cancer. 1994 May 15;73(10):2653-62 [8174066.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):568-72 [9324346.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2789-95 [10561354.001]
  • [Cites] Ann Thorac Surg. 2004 Mar;77(3):1001-6; discussion 1006-7 [14992915.001]
  • [Cites] Eur J Surg Oncol. 1994 Feb;20(1):53-6 [8131870.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1164 [10561175.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):66-72 [7834431.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1244-55 [3855683.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • [Cites] Cancer Treat Rep. 1978 Jun;62(6):865-72 [667860.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):524-31 [2065271.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):411-5 [2508462.001]
  • (PMID = 20011664.001).
  • [ISSN] 1369-1643
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2790134
  •  go-up   go-down


3. Aung L, Gorlick RG, Shi W, Thaler H, Shorter NA, Healey JH, Huvos AG, Meyers PA: Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer; 2002 Oct 15;95(8):1728-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All study patients received chemotherapy and/or surgery on one of six different protocols (T4, 5, 7, 10, 12, and CCG-7921/POG-9351).
  • Chemotherapy was scheduled for up to 40 weeks with some variations in the actual treatment period and consisted of various combinations of the following agents: high-dose methotrexate, doxorubicin, bleomycin, cyclophosphamide, dactinomycin, vincristine, cisplatin, and ifosfamide.
  • Only one had pulmonary metastasis at diagnosis and subsequent multiple recurrences that required thoracotomies and further modification of the chemotherapy regimen.
  • The median age at diagnosis for osteosarcoma was 16.6 years (range, 3.1-74.4 years).
  • The time interval from diagnosis of the primary osteosarcoma to the development of SMN was 1.3-13.1 years (median, 5.5; 95% confidence interval [CI], 3.6-9.6).
  • There were two cases of acute myeloid leukemia and one case each of myelodysplastic syndrome, non-Hodgkin lymphoma, high-grade pleomorphic sarcoma, leiomyosarcoma, fibrosarcoma, breast carcinoma, and mucoepidermoid carcinoma.
  • Although additional follow-up is warranted, the successes of current treatment regimens consisting of intensive, high-dose chemotherapy in combination with topoisomerase II inhibitors outweigh the risks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Osteosarcoma / complications. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 12365021.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip U_133 arrays containing approximately 40,000 genes/ESTs.
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


5. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nonphylloides breast sarcomas.
  • BACKGROUND: The prevalence of primary breast sarcoma is low, occurring in fewer than 1% of women with breast malignancies.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Overall median survival of patients with breast sarcoma was 58 months.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.
  • [MeSH-major] Breast Neoplasms. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW: Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol; 2008 Mar;18(3):468-76
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
  • To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy.
  • Treated tumor entities were colorectal carcinoma (CRC) (n = 12), breast cancer (BC) (n = 12), cholangiocarcinoma (CCC) (n = 10), pancreatic (n = 4), ovarian (n = 3), gastric, cervical, papillary (each n = 2), prostate, esophageal carcinoma, leiomyosarcoma (each n = 1), cancer of unknown primacy (CUP) (n = 5).
  • All patients tolerated the treatment well without any major side effects or complications.
  • HIC with gemcitabine/mitomycin is a safe, minimally invasive, palliative treatment for hepatic metastases that are progressive under systemic chemotherapy.
  • The treatment yields respectable tumor control rates in CRC and BC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Breast Neoplasms / pathology. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Oncology. 2005;69 Suppl 3:17-24 [16301832.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 16;80(2):84-9 [3278123.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Eur J Surg Oncol. 2000 Apr;26(3):209-12 [10753531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23 (22):4888-96 [16009951.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):353-61 [15758131.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):1025-34 [16944163.001]
  • [Cites] Acta Oncol. 2003;42(4):263-75 [12899497.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Eur J Surg Oncol. 2005 Nov;31(9):932-41 [15979268.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Zentralbl Chir. 1995;120(10):786-90 [7502593.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):97-101 [16028279.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):745-55 [16858591.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):53-62 [16319993.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):42-8 [11750151.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4 [8137476.001]
  • [Cites] Ther Umsch. 2006 Apr;63(4):255-61 [16689456.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4881-7 [16009952.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):922-7 [16822644.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):26-31; discussion 32 [8289448.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2203-6 [2529960.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11 Suppl):131-5 [8953600.001]
  • [Cites] Recent Results Cancer Res. 1983;86:1-12 [6647987.001]
  • [Cites] Z Gastroenterol. 2006 Jul;44(7):587-98 [16823700.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):23-7 [10073147.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):167-70 [15901375.001]
  • [Cites] Zentralbl Chir. 1998;123 Suppl 5:159-61 [10063604.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:20-9 [16368868.001]
  • [Cites] Cancer Treat Rep. 1980 Jan;64(1):31-40 [6155210.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):781-7 [15379811.001]
  • (PMID = 17938935.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Botsis D, Koliopoulos C, Kondi-Pafitis A, Creatsas G: Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report. Int J Gynecol Pathol; 2006 Apr;25(2):173-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
  • In this paper, we present a case of myxoid leiomyosarcoma development in a patient receiving tamoxifen for 3 years because of breast cancer.
  • The myxoid leiomyosarcoma should be included in the differential diagnosis of any uterine tumor with a predominantly myxomatous composition.
  • A review of the literature indicates that tamoxifen may increase not only the risk for endometrial cancer but also for uterine sarcoma, suggesting vigilance for uterine cancer in women who are being treated with this drug.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Leiomyosarcoma / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Female. Humans. Risk Factors

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


8. Munitiz V, Rios A, Canovas J, Ferri B, Sola J, Canovas P, Illana J, Parrilla P: Primitive leiomyosarcoma of the breast: case report and review of the literature. Breast; 2004 Feb;13(1):72-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive leiomyosarcoma of the breast: case report and review of the literature.
  • Sarcomas of the breast account for under 1% of breast tumours.
  • Leiomyosarcomas are less common, being a subgroup of sarcomas of the breast.
  • The case of a 58-year-old woman with a leiomyosarcoma 4 cm in diameter in the upper external quadrant of the right breast is presented.
  • The patient underwent a Madden-type modified radical mastectomy and axillary lymphadenectomy.
  • Adjuvant chemotherapy was implemented with Adriamycin (four cycles of 21 days).
  • [MeSH-major] Breast Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Mastectomy. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14759721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 24
  •  go-up   go-down


9. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, Tinar S: Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1239-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases.
  • Tamoxifen (TAM) is widely used in the treatment of breast cancer, and its paradoxical effects on female genital system are well known.
  • Four uterine sarcoma patients who had history of TAM usage for previous breast cancer are presented in this study.
  • The mean time of exposure to TAM was 6 (range 3-11) years, and the mean cumulative dose of drug was 43.82 g.
  • All patients were postmenopausal, and the mean age was 66 (range 61-73) years at the time of the diagnosis of the uterine malignancy.
  • Two (50%) patients had uterine malignant mixed müllerian tumor, and two (50%) had leiomyosarcoma.
  • All patients underwent surgery +/- adjuvant therapy (chemotherapy and/or radiation therapy), and two (50%) patients died because of the sarcoma.
  • In consequence, early detection of TAM-related uterine sarcoma is required for orderly gynecological examination in patients having history of TAM usage for previous breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Leiomyosarcoma / chemically induced. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / therapy. Combined Modality Therapy. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans. Mastectomy. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343223.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasized hemangiopericytoma of the breast: a rare case.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Anderson S, Aghajanian C: Temozolomide in uterine leiomyosarcomas. Gynecol Oncol; 2005 Jul;98(1):99-103
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Temozolomide has been studied in soft-tissue sarcomas with varying dosing schedules.
  • We review the Memorial Sloan-Kettering Cancer Center (MSKCC) experience in women with metastatic or unresectable leiomyosarcoma treated with continuous daily dose (CDD) or bolus-dose (BD) temozolomide.
  • We include a literature review of temozolomide activity in leiomyosarcoma patients.
  • METHODS: After obtaining Institutional Review Board approval, we identified women with recurrent leiomyosarcoma treated with temozolomide at MSKCC from 9/2001 to 9/2004.
  • We reviewed patients' charts for age at diagnosis, stage, performance status, prior treatments, temozolomide dose and schedule, best response to treatment, and treatment delays or dose reductions due to toxicity.
  • All patients had previously received doxorubicin; 11 had received >/=2 previous chemotherapy regimens.
  • All patients received previous doxorubicin and received >/=2 previous chemotherapy regimens.
  • One patient achieved a near complete response for 13 cycles and continues to be followed off therapy for 10+ months.
  • CONCLUSIONS: Temozolomide has promising therapeutic benefit and is well tolerated in patients with metastatic unresectable leiomyosarcoma.
  • Further investigation of temozolomide in leiomyosarcoma patients is warranted.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Leiomyosarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916799.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 16
  •  go-up   go-down


12. Le Bouëdec G, Auvray H, Curé H, de Latour M, Penault-Llorca F, Dauplat J: [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases]. Rev Med Interne; 2001 Sep;22(9):881-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases].
  • [Transliterated title] Sarcome utérin survenant au cours d'une hormonothérapie par tamoxifène. A propos de deux cas.
  • Concern has been raised about prolonged tamoxifen treatment and subsequent occurrence of endometrial adenocarcinoma; subsequent attention has been drawn through high risk histologic subtypes including poorly differentiated patterns and uterine sarcomas.
  • EXEGESIS: We report two cases of uterine sarcoma arising in postmenopausal women taking tamoxifen, 20 mg daily during 38 and 42 months, for breast carcinoma: one leiomyosarcoma and one endometrial stromal sarcoma; both cases were asymptomatic and detected by pelvic sonography.
  • CONCLUSION: Further studies will be required to establish if there is a relationship between long term tamoxifen exposure and highly aggressive types of cancer of the uterine corpus exhibiting adverse histologic features such as uterine sarcomas.

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599191.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


13. D'Adamo DR, Anderson S, Albritton K, Yamada J, Riedel E, Scheu K, Schwartz GK, Chen H, Maki RG: Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS). J Clin Oncol; 2004 Jul 15;22(14_suppl):9012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac toxicity in a phase II study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas (STS).
  • : 9012 Background:BEV (Avastin®) is an anti-VEGF monoclonal antibody with activity in colon, breast, and renal cell carcinomas.
  • Since STS are largely resistant to standard chemotherapy, we hoped to determine response rate (RR), toxicity, time to progression, and survival of pts with STS treated with BEV and DOX.
  • METHODS: Pts could have had up to 1 non-anthracycline line of therapy.
  • RESULTS: From 12/02 to 12/03 17 pts were enrolled: 13 F, 4 M; median age 54 (range 39-71); ECOG PS median 0 (range 0-2); prior therapy: surgery 12, radiation 2, chemotherapy 6.
  • 11 pts had leiomyosarcoma.
  • Four pts developed cardiac toxicity (EF<50%), three grade G2 (DOX 300, 300, 420 mg/m<sup>2</sup>) and one G3 (DOX 591 mg/m<sup>2</sup>).
  • One pt with extensive lung disease died of recurrent bilateral pneumothoraces, possibly treatment related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Falchook GS, Wheler JJ, Tannir NM, Naing A, Jackson E, Hong D, Lawhorn KN, Ng C, Amin H, Kurzrock R: Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):3555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy.
  • : 3555 Background: HIF-1α mediates adaptive responses to hypoxic conditions induced by anti-angiogenic therapy.
  • METHODS: Patients with advanced malignancy refractory to standard therapy were eligible.
  • Minor responses or stable disease lasting ≥4 months was achieved in 8 patients, including RCC (1), breast (1), leiomyosarcoma (1), nasopharyngeal (2), hepatocellular (1), neuroendocrine (1), lacrimal gland adenocystic carcinoma (1).
  • The most common drug-related toxicities observed included hypertension (36%), fatigue (34%), thrombocytopenia (29%), and myalgia (19%).
  • 22 patients (31%) experienced no drug-related toxicities greater than grade 1.
  • 56 patients (79%) experienced no drug-related toxicities greater than grade 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Rogiers X, Brunken C: Surgical management of hepatic metastatic disease. Saudi Med J; 2000 Jun;21(6):519-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical surgical resection, if possible, is the treatment of choice.
  • Radical resection of metastases from wilms-tumor, carcinoids, carcinoma of the breast, hypernephroma, adrenal tumors, malignant melanoma, leiomyosarcoma and gastric cancer may improve long time survival, however knowledge is too small for giving general directions.
  • Local destructive therapies are only beneficial when a total necrosis of the tumor is reached.
  • Indications for this treatment are quite rare.
  • Both, systemic and local chemotherapy offers only palliation with little influence on long time survival.
  • Adjuvant and neo-adjuvant chemotherapy is applicated under study conditions with encouraging results.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / pathology. Europe / epidemiology. Humans. Patient Selection. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11508246.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 17
  •  go-up   go-down


16. Grande AM, Rinaldi M, Sinelli S, D'Armini AM, Viganŏ M: Heart transplantation in chemotherapeutic dilated cardiomyopathy. Transplant Proc; 2003 Jun;35(4):1516-8
MedlinePlus Health Information. consumer health - Heart Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients (four men) experienced postchemotherapy DCM: age at time of tumour diagnosis ranged from 1-45 years (mean 13.5 +/- 19 years); interval time between tumour and HT was 3-23 years (mean 10.8 +/- 6.6) and age at HT ranged from 10-65 years (30.8 +/- 20.1).
  • Interval between end of chemotherapy and beginning of cardiac symptoms was 5.71 +/- 4.6 years.
  • Mean age at DCM diagnosis was 19.2 +/- 19.7 (range 1-50 years).
  • Interval between start of chemotherapy and DCM ranged from 1 month to 10 years (mean 3.15 +/- 3.6 years).
  • Tumours were Ewing sarcoma (7-year-old boy), paratesticular rabdomyosarcoma (1-year-old boy), Wilms tumor with pulmonary metastasis (3-year-old girl), bilateral breast carcinoma (45-year-old woman), uterine leiomyosarcoma (44-year-old woman), acute myelocytic leukemia (1.5-year-old boy and 17-year-old girl), and chronic myelocytic leukemia (5-year-old boy).
  • At follow-up (mean, 80.4 +/- 69.3 months) two patients died: a 32-year-old woman (acute myelocytic leukemia) 1 year after HT for sepsis and a 68-year-old woman who had breast adenocarcinoma recurrence 81 months after HT.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasms / classification. Neoplasms / drug therapy. Treatment Outcome


17. Burger AM, Mengs U, Kelter G, Schüler JB, Fiebig HH: No evidence of stimulation of human tumor cell proliferation by a standardized aqueous mistletoe extract in vitro. Anticancer Res; 2003 Sep-Oct;23(5A):3801-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The AME concentrations used ranged from 0.5 pg to 5 ng (0.82 fMol-85 pM) bioactive ML/ml in melanoma (HT-144, SK-MEL-28) and leiomyosarcoma (SK-MLS-1, S-UT-1B) cell lines and from 0.1-100 ng ML/ml (1.7 pM-1.7 nM) in MCF-7 breast cancer and SW620 colon carcinoma cell lines, respectively.
  • The influence of AME on cell growth was determined at various time-points from 24 hours to 6 days of exposure.
  • We found a time- and cell line-dependent inhibition of tumor cell growth, but no reproducible stimulation of tumor cell proliferation.
  • Our data clearly demonstrate that, by applying scientifically valid methods and procedures, the standardized AME did not stimulate tumor cell proliferation but showed time- and concentration-dependent antiproliferative effects.
  • [MeSH-minor] Cell Division / drug effects. Cell Line, Tumor. Growth Inhibitors / pharmacology. Humans. Inhibitory Concentration 50. Leiomyosarcoma / drug therapy. Leiomyosarcoma / pathology. Melanoma / drug therapy. Melanoma / pathology. Ribosome Inactivating Proteins, Type 2. Stimulation, Chemical. Water / chemistry

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666680.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Growth Inhibitors; 0 / Plant Preparations; 0 / Plant Proteins; 0 / Ribosome Inactivating Proteins, Type 2; 0 / Toxins, Biological; 0 / ribosome inactivating protein, Viscum; 059QF0KO0R / Water
  •  go-up   go-down


18. Kuo SH, Debnam JM, Fuller GN, de Groot J: Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology; 2009;76(1):10-8
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer patients are at high risk of this acute encephalopathy due to chronic malnutrition, chemotherapy-induced nausea and vomiting, and consumption of thiamine by rapidly growing tumors.
  • RESULTS: Five WE patients were identified and all patients had rapidly growing cancers and were undergoing active treatment.
  • All patients had poor nutritional status due to chronic nausea from chemotherapy.
  • CONCLUSION: It is crucial to consider WE in the differential diagnosis for all cancer patients with confusion.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / psychology. Confusion. Female. Humans. Leiomyosarcoma / psychology. Leukemia, Myeloid, Acute / psychology. Male. Middle Aged. Multiple Myeloma / psychology. Retrospective Studies. Risk Factors. Uterine Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018150.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Neuhaus SJ, Pinnock N, Giblin V, Fisher C, Thway K, Thomas JM, Hayes AJ: Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur J Surg Oncol; 2009 Jun;35(6):654-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution.
  • BACKGROUND: Radiation-induced sarcoma (RIS) is a rare late complication of therapeutic irradiation with a reputation for aggressive pathology and poor outcome.
  • RESULTS: Previous breast cancer was the most common indication for radiotherapy.
  • The commonest histology was leiomyosarcoma.
  • The only relationship for histology with site was for angiosarcoma (n=9), all of which developed on the chest wall/breast after irradiation for breast cancer.
  • Pedicled or free tissue transfer was required in 12 patients and abdominal or chest wall mesh reconstructions were required in 8 patients.
  • No patient received adjuvant radiotherapy but 7 received adjuvant/neoadjuvant chemotherapy.
  • [MeSH-major] Neoplasms, Radiation-Induced / therapy. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112005.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


21. Pantanowitz L, Schlecht HP, Dezube BJ: The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol; 2006 Sep;18(5):469-78
HIV InSite. treatment guidelines - Coinfection with Hepatitis Viruses and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased.
  • RECENT FINDINGS: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.
  • SUMMARY: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting.
  • Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma.
  • [MeSH-major] HIV Infections / drug therapy. Neoplasms / virology
  • [MeSH-minor] Anti-Retroviral Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Causality. Comorbidity. Humans. Incidence. Risk Factors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894295.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI 060354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 95
  •  go-up   go-down


22. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol; 2004 May 1;22(9):1706-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
  • PURPOSE: A recent report of the combination of gemcitabine and docetaxel described favorable results in patients with uterine leiomyosarcoma.
  • Additionally, cell-culture studies were performed to assess the effect of the sequence of drug administration on colony formation.
  • Cell culture studies using the SAOS-2 osteosarcoma cell line and MCF-7 breast cancer cell line were also performed.
  • Responses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant fibrous histiocytomas, malignant peripheral-nerve sheath tumors, and Ewing's sarcoma.
  • In contrast, the administration of drugs simultaneously resulted in antagonism, and docetaxel followed by gemcitabine provided mixed results.
  • A multicenter, randomized clinical trial in soft tissue sarcoma comparing gemcitabine alone with this combination, is ongoing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Interactions. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15117993.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Withanage GS, Murata H, Koyama T, Ishiwata I: Agonistic and antagonistic effects of zearalenone, an etrogenic mycotoxin, on SKN, HHUA, and HepG2 human cancer cell lines. Vet Hum Toxicol; 2001 Feb;43(1):6-10
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been suggestions of possible involvement of ZEA in the progression of breast malignancies and tumors of the female reproductive tract in humans.
  • On HepG2 cells, lower concentrations (10 nM) of 17-beta-estradiol and higher concentrations (100 microM) of ZEA exhibited toxic effects, whereas treatment with higher concentrations of 17-beta-estradiol and lower concentration of ZEA did not show toxic effects.
  • A dose dependent antagonistic effect was observed when the cell cultures were pre-incubated with ICI 182,780, a synthetic estrogen receptor blocker, before estradiol or mycotoxin treatments.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Hepatocellular / drug therapy. Endometrial Neoplasms / drug therapy. Estradiol / pharmacology. Estrogens, Non-Steroidal / agonists. Leiomyosarcoma / drug therapy. Tumor Cells, Cultured / drug effects. Zearalenone / agonists. Zeranol / therapeutic use
  • [MeSH-minor] Cell Division / drug effects. Colorimetry. Dose-Response Relationship, Drug. Female. Humans

  • Hazardous Substances Data Bank. ZEARALENONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205083.001).
  • [ISSN] 0145-6296
  • [Journal-full-title] Veterinary and human toxicology
  • [ISO-abbreviation] Vet Hum Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 0 / zearalenol; 4TI98Z838E / Estradiol; 5W827M159J / Zearalenone; 76LO2L2V39 / Zeranol
  •  go-up   go-down






Advertisement